ZA973809B - Moraxella catarrhalis outer membrane protein-106 polypeptide, gene sequence and uses thereof. - Google Patents

Moraxella catarrhalis outer membrane protein-106 polypeptide, gene sequence and uses thereof.

Info

Publication number
ZA973809B
ZA973809B ZA9703809A ZA973809A ZA973809B ZA 973809 B ZA973809 B ZA 973809B ZA 9703809 A ZA9703809 A ZA 9703809A ZA 973809 A ZA973809 A ZA 973809A ZA 973809 B ZA973809 B ZA 973809B
Authority
ZA
South Africa
Prior art keywords
polypeptide
gene sequence
membrane protein
outer membrane
moraxella catarrhalis
Prior art date
Application number
ZA9703809A
Other languages
English (en)
Inventor
Kenneth Tucker
Laura Plosila
Original Assignee
Antex Biolog Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antex Biolog Inc filed Critical Antex Biolog Inc
Publication of ZA973809B publication Critical patent/ZA973809B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C07K14/212Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734Complement-dependent cytotoxicity [CDC]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ZA9703809A 1996-05-03 1997-05-02 Moraxella catarrhalis outer membrane protein-106 polypeptide, gene sequence and uses thereof. ZA973809B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/642,712 US7341727B1 (en) 1996-05-03 1996-05-03 M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same

Publications (1)

Publication Number Publication Date
ZA973809B true ZA973809B (en) 1997-12-01

Family

ID=24577687

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9703809A ZA973809B (en) 1996-05-03 1997-05-02 Moraxella catarrhalis outer membrane protein-106 polypeptide, gene sequence and uses thereof.

Country Status (26)

Country Link
US (6) US7341727B1 (ru)
EP (1) EP0900025B1 (ru)
JP (2) JP4401437B2 (ru)
CN (2) CN100415871C (ru)
AR (1) AR006999A1 (ru)
AT (1) ATE244016T1 (ru)
AU (1) AU723528B2 (ru)
BG (1) BG64832B1 (ru)
BR (1) BR9711090A (ru)
CA (1) CA2253636C (ru)
CZ (1) CZ298034B6 (ru)
DE (1) DE69723254T2 (ru)
EA (1) EA002743B1 (ru)
EE (1) EE04684B1 (ru)
ES (1) ES2202624T3 (ru)
GE (1) GEP20022695B (ru)
HK (2) HK1021299A1 (ru)
HU (1) HU223004B1 (ru)
NO (2) NO324816B1 (ru)
NZ (1) NZ332896A (ru)
PL (3) PL189995B1 (ru)
SK (1) SK284812B6 (ru)
TW (1) TW541314B (ru)
UA (1) UA68332C2 (ru)
WO (1) WO1997041731A1 (ru)
ZA (1) ZA973809B (ru)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440425B1 (en) * 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US6335018B1 (en) * 1995-05-01 2002-01-01 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US7341727B1 (en) * 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
AUPO652897A0 (en) 1997-04-30 1997-05-29 University Of Melbourne, The Synthetic peptide constructs for the diagnosis and treatment of periodontitis
GB9714276D0 (en) 1997-07-08 1997-09-10 Univ Dundee Peptides and related compounds
US8129500B2 (en) * 1997-12-10 2012-03-06 Csl Limited Porphyromonas gingivalis polypeptides and nucleotides
GB9808720D0 (en) 1998-04-23 1998-06-24 Smithkline Beecham Biolog Novel compounds
GB9810084D0 (en) 1998-05-11 1998-07-08 Cortecs Uk Ltd Proteins
US6627728B1 (en) 1998-05-12 2003-09-30 Smithkline Beecham Biologicals S.A. Compounds from moraxella catarrhalis
GB9810193D0 (en) * 1998-05-12 1998-07-08 Smithkline Beecham Biolog Novel compounds
GB9810285D0 (en) 1998-05-13 1998-07-15 Smithkline Beecham Biolog Novel compounds
US6541616B1 (en) 1998-10-01 2003-04-01 Antex Biologics Inc. Moraxella catarrhalis protein, gene sequence and uses thereof
HU228499B1 (en) 1999-03-19 2013-03-28 Smithkline Beecham Biolog Streptococcus vaccine
US6673910B1 (en) 1999-04-08 2004-01-06 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to M. catarrhalis for diagnostics and therapeutics
WO2000071724A2 (en) * 1999-05-24 2000-11-30 Smithkline Beecham Biologicals S.A. Novel compounds from moraxella catarrhalis
GB9915031D0 (en) * 1999-06-25 1999-08-25 Smithkline Beecham Biolog Novel compounds
AU1383901A (en) * 1999-09-14 2001-04-17 Smithkline Beecham Biologicals (Sa) Novel compounds
GB9921691D0 (en) * 1999-09-14 1999-11-17 Smithkline Beecham Sa Novel compounds
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
SE0102410D0 (sv) 2001-07-04 2001-07-04 Arne Forsgren Novel surface exposed immunoglobulin D-binding protein from moraxella catarrhalis
WO2004015099A2 (en) 2002-08-02 2004-02-19 Glaxosmithkline Biologicals Sa Vaccine composition comprising lipooligosaccharide with reduced phase variability
EP2425855A1 (en) 2005-04-08 2012-03-07 Wyeth LLC Multivalent pneumococcal polysaccharide-protein conjugate composition
CN100357318C (zh) * 2005-10-11 2007-12-26 中山大学 美人鱼发光杆菌外膜蛋白w和编码序列及其制备方法和应用
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
LT3017827T (lt) 2005-12-22 2019-01-10 Glaxosmithkline Biologicals S.A. Pneumokokinė polisacharidinė konjuguota vakcina
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
ZA200805602B (en) 2006-01-17 2009-12-30 Arne Forsgren A novel surface exposed haemophilus influenzae protein (protein E; pE)
CA2652957A1 (en) 2006-06-27 2008-01-03 Oral Health Australia Pty Ltd. Porphyromonas gingivalis polypeptides useful in the prevention of periodontal disease
KR20100045445A (ko) 2007-06-26 2010-05-03 글락소스미스클라인 바이오로지칼즈 에스.에이. 스트렙토코쿠스 뉴모니애 캡슐 다당류 컨쥬게이트를 포함하는 백신
EP2176413A4 (en) 2007-07-12 2012-08-01 Oral Health Australia Pty Ltd IMMUNOLOGY TREATMENT FOR BIOFILMS
WO2009006699A1 (en) * 2007-07-12 2009-01-15 Oral Health Australia Pty Ltd Biofilm treatment
US8642046B2 (en) * 2007-10-09 2014-02-04 Tufts University Cholera vaccines
CN107266582B (zh) 2008-08-29 2021-09-10 口腔健康澳洲私人有限公司 牙龈卟啉单胞菌感染的预防、治疗和诊断
US8140041B2 (en) * 2009-08-27 2012-03-20 Mediatek Inc. Tunable capacitive device with linearization technique employed therein
ES2366735B1 (es) * 2009-10-08 2012-09-13 Fundación Pública Andaluza Para La Gestión De La Investigación En Salud De Sevilla Vacuna frente a acinetobacter baumannii.
US9700889B2 (en) 2009-11-23 2017-07-11 Cyvek, Inc. Methods and systems for manufacture of microarray assay systems, conducting microfluidic assays, and monitoring and scanning to obtain microfluidic assay results
US10065403B2 (en) 2009-11-23 2018-09-04 Cyvek, Inc. Microfluidic assay assemblies and methods of manufacture
US9855735B2 (en) 2009-11-23 2018-01-02 Cyvek, Inc. Portable microfluidic assay devices and methods of manufacture and use
US9759718B2 (en) 2009-11-23 2017-09-12 Cyvek, Inc. PDMS membrane-confined nucleic acid and antibody/antigen-functionalized microlength tube capture elements, and systems employing them, and methods of their use
CN102713621B (zh) 2009-11-23 2016-10-19 西维克公司 用于施行化验的方法和设备
US10022696B2 (en) 2009-11-23 2018-07-17 Cyvek, Inc. Microfluidic assay systems employing micro-particles and methods of manufacture
WO2013134742A2 (en) 2012-03-08 2013-09-12 Cyvek, Inc Micro-tube particles for microfluidic assays and methods of manufacture
US9500645B2 (en) 2009-11-23 2016-11-22 Cyvek, Inc. Micro-tube particles for microfluidic assays and methods of manufacture
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
JP2013521770A (ja) 2010-03-10 2013-06-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン組成物
WO2011130434A2 (en) 2010-04-13 2011-10-20 Celldex Therapeutics Inc. Antibodies that bind human cd27 and uses thereof
US8501197B2 (en) 2010-04-30 2013-08-06 The Research Foundation for The State of New York Compositions and methods for stimulating immune response against Moraxella catarrhalis
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
WO2012129455A2 (en) 2011-03-22 2012-09-27 Cyvek, Inc Microfluidic devices and methods of manufacture and use
RU2481401C2 (ru) * 2011-07-15 2013-05-10 Государственное образовательное учреждение высшего профессионального образования "Уральская государственная медицинская академия Министерства здравоохранения и социального развития Российской Федерации" (ГОУ ВПО УГМА Минздравсоцразвития России) СПОСОБ ВЫЯВЛЕНИЯ β-ЛАКТАМАЗОПРОДУЦИРУЮЩИХ ОКСИДАЗОПОЗИТИВНЫХ ГРАМОТРИЦАТЕЛЬНЫХ ДИПЛОКОККОВ, ПОДОЗРИТЕЛЬНЫХ НА ПРИНАДЛЕЖНОСТЬ К MORAХELLA (BRANCHAMELLA) CATARRHALIS
US11210432B2 (en) * 2013-08-20 2021-12-28 Janus Technologies, Inc. Method and apparatus for selectively snooping and capturing data for secure computer interfaces
EP3268037B1 (en) 2015-03-09 2022-08-31 Celldex Therapeutics, Inc. Cd27 agonists
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
US10228367B2 (en) 2015-12-01 2019-03-12 ProteinSimple Segmented multi-use automated assay cartridge
EP3445783A2 (en) 2016-04-18 2019-02-27 Celldex Therapeutics, Inc. Agonistic antibodies that bind human cd40 and uses thereof
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
JP7291633B2 (ja) 2017-05-30 2023-06-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム アジュバントを製造する方法
CA3083078A1 (en) 2017-12-01 2019-06-06 Glaxosmithkline Biologicals Sa Saponin purification
BR112020021271A2 (pt) 2018-04-17 2021-01-26 Celldex Therapeutics, Inc. construtos bispecíficos e anticorpos anti- cd27 e anti-pd-l1
MX2021001479A (es) 2018-08-07 2021-04-28 Glaxosmithkline Biologicals Sa Novedosos procesos y vacunas.
CN111157735B (zh) * 2018-11-07 2023-02-07 广州万孚生物技术股份有限公司 凝集性卡他莫拉菌单克隆抗体及其制备方法和应用
US20220339282A1 (en) 2018-11-29 2022-10-27 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
WO2020123444A1 (en) 2018-12-11 2020-06-18 Celldex Therapeutics, Inc. Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
US20220235095A1 (en) 2019-06-05 2022-07-28 Glaxosmithkline Biologicals Sa Saponin purification
CN111778226B (zh) * 2020-07-21 2022-04-05 东北师范大学 一种水稻耐碱胁迫相关的质膜H+-ATPase蛋白及其应用
AU2022253269A1 (en) 2021-04-09 2023-11-23 Celldex Therapeutics, Inc. Antibodies against ilt4, bispecific anti-ilt4/pd-l1 antibody and uses thereof
WO2023077521A1 (en) 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage
WO2024017827A1 (en) 2022-07-19 2024-01-25 Glaxosmithkline Biologicals Sa Continuous process for vaccine production

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675176A (en) * 1983-12-12 1987-06-23 Norden Laboratories Moraxella bovis protease vaccine
US4879213A (en) * 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
US5552146A (en) * 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
US5607846A (en) 1994-05-17 1997-03-04 Research Foundation Of State University Of New York Vaccine for moraxella catarrhalis
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US6335018B1 (en) * 1995-05-01 2002-01-01 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US7341727B1 (en) * 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
GB9809683D0 (en) * 1998-05-06 1998-07-01 Smithkline Beecham Biolog Novel compounds
GB9812163D0 (en) * 1998-06-05 1998-08-05 Smithkline Beecham Biolog Novel compounds

Also Published As

Publication number Publication date
NO985113D0 (no) 1998-11-02
CN1222618C (zh) 2005-10-12
BG102983A (en) 2000-05-31
EA002743B1 (ru) 2002-08-29
US20070087019A1 (en) 2007-04-19
EE04684B1 (et) 2006-08-15
HUP9902695A3 (en) 2001-02-28
EP0900025A1 (en) 1999-03-10
AU3118097A (en) 1997-11-26
BG64832B1 (bg) 2006-06-30
US7128910B2 (en) 2006-10-31
PL189375B1 (pl) 2005-07-29
CN1800359A (zh) 2006-07-12
US20080145916A1 (en) 2008-06-19
DE69723254D1 (de) 2003-08-07
BR9711090A (pt) 1999-08-17
CN100415871C (zh) 2008-09-03
AR006999A1 (es) 1999-10-13
NO20063711L (no) 1998-12-28
US20100021492A1 (en) 2010-01-28
US7576179B2 (en) 2009-08-18
PL330935A1 (en) 1999-06-07
SK284812B6 (sk) 2005-12-01
DE69723254T2 (de) 2004-04-22
CZ298034B6 (cs) 2007-05-30
NO985113L (no) 1998-12-28
TW541314B (en) 2003-07-11
AU723528B2 (en) 2000-08-31
EE9800373A (et) 1999-04-15
HK1095358A1 (en) 2007-05-04
ATE244016T1 (de) 2003-07-15
SK150998A3 (en) 1999-05-07
US6214981B1 (en) 2001-04-10
CZ352498A3 (cs) 1999-06-16
PL189995B1 (pl) 2005-10-31
GEP20022695B (en) 2002-05-27
PL189374B1 (pl) 2005-07-29
NZ332896A (en) 2000-05-26
EP0900025B1 (en) 2003-07-02
US7914795B2 (en) 2011-03-29
CN1223549A (zh) 1999-07-21
NO324816B1 (no) 2007-12-10
CA2253636C (en) 2003-04-22
WO1997041731A1 (en) 1997-11-13
US20020177200A1 (en) 2002-11-28
UA68332C2 (en) 2004-08-16
EP0900025A4 (en) 2000-01-05
ES2202624T3 (es) 2004-04-01
CA2253636A1 (en) 1997-11-13
HU223004B1 (hu) 2004-03-01
EA199800973A1 (ru) 1999-06-24
US7341727B1 (en) 2008-03-11
HK1021299A1 (en) 2000-06-09
JP2000510696A (ja) 2000-08-22
HUP9902695A2 (hu) 1999-12-28
JP4401437B2 (ja) 2010-01-20
JP2008161194A (ja) 2008-07-17

Similar Documents

Publication Publication Date Title
ZA973809B (en) Moraxella catarrhalis outer membrane protein-106 polypeptide, gene sequence and uses thereof.
HK1017257A1 (en) Pharmaceutical composition for immunomodulation based on peptides and adjuvants.
AU7299796A (en) Cellulases, the genes encoding them and uses thereof
EP0571442A4 (en) CYTOKIN INDUCIBLE PROTEIN TSG-14, ITS ENCODING DNA AND THEIR USE.
AU3274995A (en) Fibrin-binding peptides, dna coding therefor and uses thereof
AUPN999096A0 (en) Peptides, antibodies, vaccines & uses thereof
AU6410099A (en) (moraxella catarrhalis) protein, nucleic acid sequence and uses thereof
HK1001404A1 (en) Isolated, tyrosinase derived peptides and uses thereof.
ZA974084B (en) Novel α-glucuronidases, production hereof and their uses.
ZA972726B (en) Anti-Fas recombinant antibodies and DNA therefor.
EP0669396A4 (en) Novel polypeptides and DNA coding for them.
ZA974286B (en) The spindly gene, methods of identification and use.
ZA969402B (en) Novel oligopeptides, the preparation and use thereof.
ZA972186B (en) Lytic peptides.
AU4033199A (en) Polypeptides from moraxella (branhamella) catarrhalis
AU3670395A (en) Hippocampus-associated proteins, dna sequences coding therefor and uses thereof
ZA991443B (en) Leptospiral major outer membrane protein, LipL32.
ZA987660B (en) Novel tissue-specific calpains, their preparation and use.
HUP0103945A3 (en) Moraxella catarrhalis basb034 polypeptides and uses thereof
AU5137698A (en) Novel dna, novel protein, and novel antibody
HUP0102235A3 (en) Basbo27 proteins and genes from moraxella catarrhalis, antigens, antibodies, and uses
AU6844596A (en) Nucleotide sequence encoding the cd33-like protein
ZA9711401B (en) Polypeptide of the bHLH family, corresponding nucleic acid sequence.
ZA9610510B (en) Novel peptides, the preparation and use thereof.
AU7519100A (en) Moraxella catarrhalis antigen, corresponding gene and uses thereof